Source: http://hypertension.zaslavsky.com.ua/article/view/82707
Timestamp: 2019-04-24 21:57:29+00:00

Document:
The aim of research: to study of clinical and cardioprotective efficacy of 12-week indapamide monotherapy in patients with mild to moderate hypertension.
Materials and Methods of Study. The study included 33 patients with essential hypertension stage I–II and hypertension of 1–2 degree (mild to moderate) (ESH/ESC 2007), males and females, mean age was 47.61 ± 9.62 years, mean duration of disease — 6.21 ± 4.31 years. As antihypertensive therapy we administered indapamide 2.5 mg/day. Echocardiography was performed in accordance with American Society of Echocardiography Guidelines in the M- and B-mode on the device of ultrasound EnVisor C (Philips, Holland).
The Results of Study. During the 12-week monotherapy with indapamide there was marked a high antihypertensive efficacy of this agent in patients with mild to moderate hypertension with the achievement of the target level of systolic and diastolic blood pressure in 75.6 % of patients. High antihypertensive efficacy of the drug was also characterized by reliable cardioprotection, regression of left ventricular hypertrophy in 52 % of patients, reduction of left ventricular mass index by 10.86 %.
Conclusion. Indapamide as monotherapy is recommended as antihypertensive drug, which has cardioprotective efficacy, for treatment patients with mild to moderate hypertension.
Глезер М.Г. Соль и диуретики на арене лечения артериальной гипертензии. — М.: Медиком, 2013. — 16 с.
Грачев А.В. Центральные и периферические механизмы адаптации сердечно-сосудистой системы у больных артериальной гипертонией (патогенетические и терапевтические аспекты): Дис... д-ра мед. наук. — Ташкент, 2001. — 364.
Грачев А.В., Аляви А.Л., Мостовщиков С.Б. и др. К вопросу о гемодинамической норме в кардиологических исследованиях // Мед. журнал Узбекистана. — 2001. — № 3 (2). — С. 43-48.
Мычка В.Б., Чазова И.Е. Российская доказательная медицина — программа МИНОТАВР: преимущества ретардной формы индапамида при лечении метаболического синдрома // Consilium medicum. — 2006. — 8 (5). — 46-50.
Преображенский Д.В., Сидоренко Б.А., Алехин М.Н. и др. Гипертрофия левого желудочка при гипертонической болезни. Часть I. Критерии диагностики гипертрофии левого желудочка и ее распространенность // Кардиология. — 2003. — 10. — 99-104.
Ю.Н. Беленков, Е.О. Борисова и др. — М.: Литтерра, 2004. — 972 с.
Шляхто Е.В., Конради А.О. Структурно-функциональные изменения миокарда у больных гипертонической болезнью // Кардиология. — 1999. — № 6. — С. 78-82.
Шляхто Е.В., Конради А.О. Зачем и как лечить гипертрофию левого желудочка? // Артериальная гипертензия. — 2002. — Т. 8, № 2.
Amouyel P. The concept of individual cardiovascular risk ma-nagement // Eur. Heart J. — 2000. — № 2. — P. D2-D4.
Canau A., Devereux R.B., Roman M.J. et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension // J. Am. Coll. Cardiol. — 1992. — V. 19. — P. 1550-1558.
Curri C., Robinson H., Brown R. et al. Regression of left ventricular hypertrophy in patients with essential hypertension. Results of 6 month treatment with indapamide // Amer. J. Hypertension. — 1996. — Vol. 9. — P. 828-832.
Devereux R.B., Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method // Circulation. — 1977. — V. 55. — P. 613-618.
Devereux R., Pini R., Aurigeunna G., Roman M. Measurement of left ventricular mass: methodology and expertise // J. Hypertens. — 1997. — V. 15. — Р. 801-809.
2003 European Society of Hypertension — European Society Cardiology. Guidelines for the management of arterial Hypertension. Guidelines Committee // J. Hypertens. — 2003. — № 21. — Р. 1011-1053.
Gosse P., Sheridan D.J., Zannad F. Regression of the left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg vs enalapril 20 mg: the LIVE study // J. Hypertension. — 2000. — 18 (10). — 1465-75.
Kannel W.B. Left ventricular hypertrophy as a risk factor in arterial hypertension // Eur. Heart. J. — 1996. — № 13, Suppl. D. — 82-88.
Mancia G., De Backer G., Dominiczak A. et al. Task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 guidelines for the management of arterial hypertension // Eur. Heart J. — 2007. — V. 28. — Р. 1462-1536.
Owens G.K., Schwartz S.M. Alterations in vascular smooth muscle mass in the spontaneously hypertensive rat. Role of cellular hypertrophy, hyperpliody and hyperplasia // Circ. Res. — 1982. — № 51. — Р. 280-289.
Savage D.D., Drayer J.I.M., Henry W.L. et al. Echocardiographic assessment of cardiac anatomy and function in hypertensive patients // Circulation. — 1979. — V. 59. — P. 623-636.
Sahn D.J., Demaria A., Kisslo J. et al. Recommendation regarding quantitation in M-mode echocardiography. Results of a survey of echocardiographic measurements // Circulation. — 1987. — V. 58. — Р. 1072-1082.
Sharabi Y., Grossman E., Nussinovitch N. et al. Indapamide- a substitute diuretic for hypertensives with hyperglycemia and dyslipidemia // Harefuah. — 1996. — Vol. 131. — P. 233-236.
Teichholtz L.E., Kruelen T., Herman M.V., Gorlin R. Problems in echocardiographic volume determination // Am. J. Cardiol. — 1976. — V. 37. — Р. 7-11.
Verdecchia P., Porcellati C., Zampi I. Asymmetric left ventricular remodeling due to isolated septal thickening in patients with systemic hypertension and normal left ventricular masses // Am. J. Cardiol. — 1994. — № 73. — Р. 247-252.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.